within Pharmacolibrary.Drugs.ATC.J;

model J01MB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 2.3333333333333336e-06,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.003,
    Tlag           = 0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01MB02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Nalidixic acid is a first-generation synthetic quinolone antibiotic. It is primarily effective against Gram-negative bacteria and was initially used to treat urinary tract infections (UTIs). However, due to widespread resistance and the development of newer fluoroquinolones with better efficacy and safety profiles, nalidixic acid is rarely used today and is no longer approved or recommended in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Campoli-Richards, DM, et al., &amp; Ward, A (1988). Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. <i>Drugs</i> 35(4) 373–447. DOI:<a href=\"https://doi.org/10.2165/00003495-198835040-00003\">10.2165/00003495-198835040-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3292209/\">https://pubmed.ncbi.nlm.nih.gov/3292209</a></p></li><li><p>D&#x27;Arcy, PF (1985). Nitrofurantoin. <i>Drug intelligence &amp; clinical pharmacy</i> 19(7-8) 540–547. DOI:<a href=\"https://doi.org/10.1177/106002808501900706\">10.1177/106002808501900706</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3896715/\">https://pubmed.ncbi.nlm.nih.gov/3896715</a></p></li><li><p>Rodvold, KA, &amp; Piscitelli, SC (1993). New oral macrolide and fluoroquinolone antibiotics: an overview of pharmacokinetics, interactions, and safety. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 17 Suppl 1 S192–S199. DOI:<a href=\"https://doi.org/10.1093/clinids/17.supplement_1.s192\">10.1093/clinids/17.supplement_1.s192</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8399914/\">https://pubmed.ncbi.nlm.nih.gov/8399914</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01MB02;
